CMS Advisory Committee Considers Prognostic Value of Tests Being Used in Predictive Fashion | GenomeWeb

NEW YORK (GenomeWeb) – After reviewing data presented to them on a range of genetic tests already in clinical use for personalizing cancer treatments, an advisory group for the Centers for Medicare & Medicaid Services voted this week that two well-established breast cancer recurrence risk tests and microsatellite instability (MSI) testing in colorectal cancer have sufficient prognostic validity and utility.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.